Preclinical assessment of an antibody–PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells

Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody–Drug Conjugate Targeting 5T4

(2017) Jay Harper et al.   MOLECULAR CANCER THERAPEUTICS

5T4-Targeted Therapy Ablates Cancer Stem Cells and Prevents Recurrence of Head and Neck Squamous Cell Carcinoma

(2016) Samuel A. Kerk et al.   CLINICAL CANCER RESEARCH

Design and Synthesis of Tesirine, a Clinical Antibody–Drug Conjugate Pyrrolobenzodiazepine Dimer Payload

(2016) Arnaud C. Tiberghien et al.   ACS Medicinal Chemistry Letters

Clonogenic multiple myeloma cells have shared stemness signature associated with patient survival

(2015) Renji Reghunathan et al.   Oncotarget

Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma

(2014) Y.-T. Tai et al.   BLOOD

Curing myeloma at last: defining criteria and providing the evidence

(2014) B. Barlogie et al.   BLOOD

Implications of Heterogeneity in Multiple Myeloma

(2014) Sanjay de Mel et al.   Biomed Research International

Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma

(2013) Chungyee Leung-Hagesteijn et al.   CANCER CELL

B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma

(2013) R. O. Carpenter et al.   CLINICAL CANCER RESEARCH

Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival

(2012) Eric Sanchez et al.   BRITISH JOURNAL OF HAEMATOLOGY

Multiple Myeloma Cancer Stem Cells

(2008) Carol Ann Huff et al.   JOURNAL OF CLINICAL ONCOLOGY